Cargando…

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease

Dopaminergic therapies dominate the treatment of the motor and non-motor symptoms of Parkinson’s disease (PD) but there have been no major advances in therapy in many decades. Two of the oldest drugs used appear more effective than others—levodopa and apomorphine—but the reasons for this are seldom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jenner, P., Falup-Pecurariu, C., Leta, V., Verin, M., Auffret, M., Bhidayasiri, Roongroj, Weiss, D., Borovečki, F., Jost, W. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2023
Materias:	Neurology and Preclinical Neurological Studies - Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645644/ https://www.ncbi.nlm.nih.gov/pubmed/37210460 http://dx.doi.org/10.1007/s00702-023-02655-0

Ejemplares similares

Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience
por: Henriksen, Tove, et al.
Publicado: (2023)

Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease
por: Diaconu, Ştefania, et al.
Publicado: (2023)

Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
por: Tall, P., et al.
Publicado: (2023)

Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
por: Auffret, Manon, et al.
Publicado: (2023)

Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study
por: Zagnoli, Fabien, et al.
Publicado: (2023)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

Dry eye in Parkinson's disease: a narrative review
por: Ungureanu, Larisa, et al.
Publicado: (2023)

Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome
por: Grund, K. E., et al.
Publicado: (2023)

Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
por: Gaire, Suman, et al.
Publicado: (2021)

We Move or Are We Moved? Unpicking the Origins of Voluntary Movements to Better Understand Semivoluntary Movements
por: Virameteekul, Sasivimol, et al.
Publicado: (2022)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

Editorial: Movement Disorders and Sleep – Underlying Mechanisms, Clinical Aspects and Treatment
por: Falup-Pecurariu, Cristian, et al.
Publicado: (2019)

Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
por: Mizuno, Yoshikuni, et al.
Publicado: (2017)

Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A post hoc analysis of the SETTLE study
por: Bhidayasiri, Roongroj, et al.
Publicado: (2023)

Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson’s disease
por: Müller, Thomas, et al.
Publicado: (2020)

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
por: Palacios, Natalia, et al.
Publicado: (2021)

Apprends-moi l'art des petits pas: Levodopa, Carbidopa Intestinal Gel plus Entacapone
por: Jost, Wolfgang H.
Publicado: (2023)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Effects of Levodopa on Impairments to High-Level Vision in Parkinson's Disease
por: Anderson, Stephen, et al.
Publicado: (2020)

Home initiation of apomorphine infusion: lessons from the COVID-19 pandemic and implications for current clinical practice
por: Kobylecki, Christopher, et al.
Publicado: (2023)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Differences in Levodopa Response for Progressive and Non-Progressive Micrographia in Parkinson's Disease
por: Zham, Poonam, et al.
Publicado: (2021)

Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia
por: Sgroi, Stefania, et al.
Publicado: (2018)

The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
por: Auffret, Manon, et al.
Publicado: (2018)

Cost-Effectiveness of Apomorphine Sublingual Film as an “On-Demand” Treatment for “OFF” Episodes in Patients with Parkinson’s Disease
por: Thach, Andrew, et al.
Publicado: (2021)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Wang, Libo, et al.
Publicado: (2018)

Case report: Levodopa-responsive parkinsonism with akinetic mutism after ventriculo-peritoneal shunt
por: Zhang, Ying, et al.
Publicado: (2023)

Botulinum Neurotoxin-A Injection in Adult Cervical Dystonia and Spastic Paresis: Results From the INPUT (INjection Practice, Usage and Training) Survey
por: Chung, Tae Mo, et al.
Publicado: (2020)

Chaudhuri’s Dashboard of Vitals in Parkinson’s syndrome: an unmet need underpinned by real life clinical tests
por: Qamar, Mubasher A., et al.
Publicado: (2023)

Correction to: The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
por: Auffret, Manon, et al.
Publicado: (2018)

Slurring of Speech and Lip Paresthesia: Symptoms of Levodopa End of Dose Wearing Off in Parkinson's Disease
por: Nasir, Usama, et al.
Publicado: (2018)

Polymorphism of the Dopa-Decarboxylase Gene Modifies the Motor Response to Levodopa in Chinese Patients With Parkinson's Disease
por: Li, Lanting, et al.
Publicado: (2020)

The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience
por: Băjenaru, O., et al.
Publicado: (2015)

Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum
por: Leta, Valentina, et al.
Publicado: (2021)

Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Carbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design
por: Brodell, David W, et al.
Publicado: (2012)

Anxiety and Levodopa Equivalent Daily Dose Are Potential Predictors of Sleep Quality in Patients With Parkinson Disease in Taiwan
por: Chang, Chun-Wei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vusbbou0qlbp9bue48h51j9g8b